Unknown

Dataset Information

0

Natalizumab therapy for multiple sclerosis.


ABSTRACT: The treatment of relapsing remitting multiple sclerosis has witnessed major progress since the first effective disease modifying treatment, ß-interferon, became available in 1993. One of the most remarkable new treatments has been natalizumab. This review describes the evolution of this humanized anti-?4ß1 monoclonal antibody, from preclinical experimental research through proof-of-concept (phase 1/2) and pivotal (phase 3) clinical trials to the now extensive experience of its use in clinical practice. The future potential and challenges of natalizumab and oral therapies with a similar mechanism of action are also discussed.

SUBMITTER: Chataway J 

PROVIDER: S-EPMC3557363 | biostudies-literature | 2013 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Natalizumab therapy for multiple sclerosis.

Chataway Jeremy J   Miller David H DH  

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 20130101 1


The treatment of relapsing remitting multiple sclerosis has witnessed major progress since the first effective disease modifying treatment, ß-interferon, became available in 1993. One of the most remarkable new treatments has been natalizumab. This review describes the evolution of this humanized anti-α4ß1 monoclonal antibody, from preclinical experimental research through proof-of-concept (phase 1/2) and pivotal (phase 3) clinical trials to the now extensive experience of its use in clinical pr  ...[more]

Similar Datasets

| S-EPMC4011812 | biostudies-other
| S-EPMC4299884 | biostudies-other
| S-EPMC5497532 | biostudies-other
| S-EPMC8573181 | biostudies-literature
| S-EPMC8549024 | biostudies-literature
| S-EPMC3858305 | biostudies-literature
| S-EPMC4402083 | biostudies-other
| S-EPMC6389745 | biostudies-literature
| S-EPMC8795211 | biostudies-literature
| S-EPMC8699923 | biostudies-literature